LYTIX BIOPHARMA ASA: årsregnskap 2016 vs 2015
Shrank 13% on revenue, weaker earnings
approved 2017-06-27; registry 2017-07-11; journal 2017 648516
Summary
What changed
Comparing Årsregnskap 2016 with 2015 for LYTIX BIOPHARMA ASA. Revenue 15.22m NOK → 13.17m NOK (-13.5%). Net result -55.19m NOK → -67.83m NOK. Equity 88.80m NOK → 29.79m NOK.
On the constructive side: cash rose. Pressures included: revenue fell; operating result weakened; net result weakened.
Also worth watching: paid-in equity reduced; book investments changed. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Cash rose
Bank deposits 8.64m NOK → 18.05m NOK (+108.9% YoY). Calculated
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 15.22m NOK to 13.17m NOK (-13.5% YoY). Calculated
-
↓
Operating result weakened
Operating result -55.54m NOK → -64.47m NOK (op. margin -364.8% → -489.4%). Calculated
-
↓
Net result weakened
Net result -55.19m NOK → -67.83m NOK (net margin -362.5% → -514.9%). Calculated
-
↓
Equity eroded
Book equity 88.80m NOK → 29.79m NOK (equity ratio 81.8% → 72.4%). Calculated
-
↓
Payroll up without matching revenue
Salary cost 20.13m NOK → 22.44m NOK (132% → 170% of revenue). Calculated
Things to notice
-
·
Paid-in equity reduced
Paid-in equity fell 88.80m NOK → 29.79m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Book investments changed
Investment / intangible book value 6.36m NOK → 9.36m NOK. Reported fact